

1 Pathogenesis of *Escherichia coli* from polymicrobial Urinary tract infections

2 3 Response to Piatti:

4
5 Gemma Croxall and Alan McNally

6
7 Pathogen Research Group, Nottingham Trent University, Clifton Lane, Nottingham
8 NG11 8NS

9
10 On behalf of the authors of our manuscript on pathogenesis of *E. coli* from
11 polymicrobial urinary tract infections (Croxall *et al.*, 2011), we present a response to
12 the correspondence submitted by Gabriella Piatti. We thank the author for their
13 interest in our work, and especially welcome their comment on the importance of
14 studying such infections. We also hereby attempt to clarify some points of confusion
15 in the authors interpretation of the data displayed in the initial publication.

16
17 Piatti begins by stating that our analysis of antimicrobial resistance data was
18 (probably) performed regardless of patient group. We clearly state in our manuscript
19 that there was no difference in levels of antimicrobial resistance between
20 polymicrobial and monomicrobial samples. As there was no statistically significant
21 difference we chose not to present that data in detail given the amount of data we had
22 to present on what we considered our significant findings, namely that polymicrobial
23 UTI contain high numbers of organisms with significant levels of antimicrobial
24 resistance and high levels of invasiveness and are going untreated in clinical settings.
25 The author is correct that this is not in agreement with previous literature, and that is a
26 key reason why we believe our study and others like it need to be conducted and
27 published. Only by performing controlled, co-ordinated equivalent studies across
28 multiple sites can a true evaluation of organisms circulating in polymicrobial UTI be
29 determined and compared. We believe this to be of immediate requirement in the field,
30 particularly when one considers comparisons of primary secondary and tertiary
31 healthcare facilities, as well as geographical variations in circulating bacterial
32 populations.

33
34 Piatti goes on to explain that the simultaneous discovery of enhanced ciprofloxacin
35 resistance and increased pathogenic potential is in their opinion contradictory, and
36 that we have not compared “virulence genes” across our isolates. Additionally there is
37 a suggestion that without full analysis there is “doubt on the real significance of our
38 findings”. Firstly, we do not consider enhanced resistance and pathogenesis within a
39 population of *E. coli* as contradictory at all. Particular attention has recently been paid
40 to the emergence of strains such as *E. coli* ST131 which is both highly resistant and
41 pathogenic. Additionally when viewing our results as a population it is clear there will
42 be some strains which have increased resistance and some which have increased
43 pathogenesis, and that the results cannot be generalised as all *E. coli* displaying both
44 phenotypes. The study of the population was outwith the scope of our manuscript,
45 which we state clearly in abstract, introduction and discussion is about highlighting
46 the presence of potentially dangerous pathogens in UTI samples that go untreated.
47 Similarly the presence of “virulence genes” would need to have been conducted at the
48 level of our *E. coli* population, outwith the scope of our manuscript. The author will
49 be pleased to know that a comprehensive analysis of the *E. coli* population was
50 conducted, and is currently under review for publication in another journal. In that

51 work the entire population is genotyped by MLST and the VAG multiplex PCR they
52 refer to (Johnson & Stell, 2000) and correlated to antimicrobial resistance on a strain
53 by strain basis. The debate of “virulence genes” is a contentious one also, particularly
54 in ExPEC where it would appear there is no real virulence gene signature to speak of,
55 rather that *E. coli* has a vast array of tools to choose from the accessory gene pool
56 within which there is enormous overlap and redundancy (Barl *et al.*, 2008,
57 Bielaszewska *et al.*, 2007, Brzuszkiewicz *et al.*, 2006, Dobrindt *et al.*, 2004).

58
59 One final point from Piatti is that when studying ciprofloxacin resistance we did so
60 only in elderly patients and did not analyse catheterised –v- non-catheterised patients.
61 We state in the manuscript a comparison between those 2 groups showing no
62 significant difference. Indeed most of our comparative analyses across those 2 groups
63 were not significant, primarily due to the sampling bias given to allow collection of
64 primarily polymicrobial samples, and therefore far fewer catheterised patients. The
65 reason this was done is the same as the reason we studied elderly patients, namely that
66 the funding generously received from the Dowager Countess Eleanor Peel trust was to
67 study the potential pathogens present in, and going untreated in, polymicrobial UTI in
68 elderly patients, as made clear throughout the presentation of our work. Undoubtedly
69 our findings have opened up the possibility of similar studies across wider cohorts,
70 and we encourage Piatti and others to join us in studying this topic to a much greater
71 level.

72 73 **References:**

74 **Barl, T., Dobrindt, U., Yu, X., Katcoff, D. J., Sompolinsky, D., Bonacorsi, S.,**
75 **Hacker, J. & Bachmann, T. T. (2008).** Genotyping DNA chip for the simultaneous
76 assessment of antibiotic resistance and pathogenic potential of extraintestinal
77 pathogenic *Escherichia coli*. *Int. J. Antimicrob. Agents* **32**, 272-277.

78 **Bielaszewska, M., Dobrindt, U., Gartner, J., Gallitz, I., Hacker, J., Karch, H.,**
79 **Muller, D., Schuberte, S., Schmidt, M. A. & other authors (2007).** Aspects of
80 genome plasticity in pathogenic *Escherichia coli*. *Internat. J. Med. Microbiol.* **297**,
81 625-639.

82 **Brzuszkiewicz, E., Bruggemann, H., Liesegang, H., Emmerth, M., Olschlager, T.,**
83 **Nagy, G., Albermann, K., Wagner, C., Buchrieser, C. & other authors (2006).**
84 How to become a uropathogen: comparative genomic analysis of extraintestinal
85 pathogenic *Escherichia coli* strains. *Proc Nat Acad Sci U S A.* **103**, 12879-84.

86 **Croxall, G., Weston, V., Joseph, S., Manning, G., Cheetham, P. & McNally, A.**
87 **(2011).** Increased Human Pathogenic Potential of *Escherichia coli* from
88 Polymicrobial Urinary Tract Infections in Comparison to Isolates from
89 Monomicrobial Culture Samples. *J. Med Microbiol.* **60**, 102-102-109.

90 **Dobrindt, U., Hochhut, B., Hentschel, U. & Hacker, J. (2004).** Genomic islands in
91 pathogenic and environmental microorganisms. *Nat Rev Microbiol* **2**, 414-424.

92 **Johnson, J. R. & Stell, A. L. (2000).** Extended virulence genotypes of *Escherichia*
93 *coli* strains from patients with urosepsis in relation to phylogeny and host compromise.
94 *J. Infect. Dis.* **181**, 261-272.